1. Home
  2. INZY vs III Comparison

INZY vs III Comparison

Compare INZY & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INZY
  • III
  • Stock Information
  • Founded
  • INZY 2015
  • III 2006
  • Country
  • INZY United States
  • III United States
  • Employees
  • INZY N/A
  • III N/A
  • Industry
  • INZY Biotechnology: Pharmaceutical Preparations
  • III Professional Services
  • Sector
  • INZY Health Care
  • III Consumer Discretionary
  • Exchange
  • INZY Nasdaq
  • III Nasdaq
  • Market Cap
  • INZY 256.3M
  • III 227.5M
  • IPO Year
  • INZY 2020
  • III 2007
  • Fundamental
  • Price
  • INZY N/A
  • III $5.16
  • Analyst Decision
  • INZY Buy
  • III Buy
  • Analyst Count
  • INZY 9
  • III 1
  • Target Price
  • INZY $15.22
  • III $5.50
  • AVG Volume (30 Days)
  • INZY 989.2K
  • III 206.0K
  • Earning Date
  • INZY 08-05-2025
  • III 08-04-2025
  • Dividend Yield
  • INZY N/A
  • III 3.52%
  • EPS Growth
  • INZY N/A
  • III N/A
  • EPS
  • INZY N/A
  • III 0.16
  • Revenue
  • INZY N/A
  • III $242,899,000.00
  • Revenue This Year
  • INZY N/A
  • III N/A
  • Revenue Next Year
  • INZY N/A
  • III $5.08
  • P/E Ratio
  • INZY N/A
  • III $32.64
  • Revenue Growth
  • INZY N/A
  • III N/A
  • 52 Week Low
  • INZY $0.72
  • III $2.95
  • 52 Week High
  • INZY $6.24
  • III $5.15
  • Technical
  • Relative Strength Index (RSI)
  • INZY 82.67
  • III 67.10
  • Support Level
  • INZY $3.94
  • III $4.51
  • Resistance Level
  • INZY $3.97
  • III $4.79
  • Average True Range (ATR)
  • INZY 0.01
  • III 0.14
  • MACD
  • INZY -0.08
  • III 0.02
  • Stochastic Oscillator
  • INZY 100.00
  • III 93.75

About INZY Inozyme Pharma Inc.

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.

About III Information Services Group Inc.

Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.

Share on Social Networks: